×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OTLK – outlook therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OTLK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
04:32 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/24
09:05 am
otlk
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/21
02:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/13
08:30 am
otlk
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Medium
Report
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
11/3
08:35 am
otlk
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Neutral
Report
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
10/31
01:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
9/30
08:05 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
9/29
08:52 am
otlk
Outlook Therapeutics Provides Update on Type A Meeting with FDA [Yahoo! Finance]
High
Report
Outlook Therapeutics Provides Update on Type A Meeting with FDA [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
8/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
15.7%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
3.9%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
1.6%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
-1.6%
outlook therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/3
05:01 pm
otlk
Form 8-K Outlook Therapeutics, For: Nov 03
Medium
Report
Form 8-K Outlook Therapeutics, For: Nov 03
10/21
09:01 am
otlk
Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: Empery Asset Management, LP
Low
Report
Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: Empery Asset Management, LP
10/3
08:37 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Huang Andong
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Huang Andong
10/3
08:12 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Haller Julia A
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Haller Julia A
10/3
07:55 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: HILZINGER KURT J
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: HILZINGER KURT J
10/3
07:45 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Gangolli Julian S
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Gangolli Julian S
10/3
07:21 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Haddadin Yezan Munther
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Haddadin Yezan Munther
10/3
07:15 pm
otlk
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Auffarth Gerd
Low
Report
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Auffarth Gerd
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/15
Form 10-Q Outlook Therapeutics, For: Mar 31
62.8%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
TOP News Decliners
12/23
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
-50.0%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: